三黄泻心汤“炮制配伍”活血化瘀优势方抗大鼠动脉粥样硬化作用的研究

中国药物警戒 ›› 2017, Vol. 14 ›› Issue (9): 518-522.

三黄泻心汤“炮制配伍”活血化瘀优势方抗大鼠动脉粥样硬化作用的研究

殷小杰, 马晓静, 王岚, 贡磊磊, 李丽, 肖永庆, 梁日欣^*

中国中医科学院中药研究所,北京 100700

收稿日期:2017-11-06 修回日期:2017-11-06 出版日期:2017-09-20 发布日期:2017-11-06
通讯作者: 梁日欣,女,研究员,心脑血管药理学研究。E-mail：liangrixin2009@sina.com
作者简介:殷小杰,男,主管技师,心脑血管药理学研究。
基金资助:
国家自然基金面上项目（81274087）：炮制配伍“三黄泻心汤”的成分组合优化及优势方的作用机理研究

Effect of Compound Compatibility of Processed Sanhuangxiexin Decoction with Activating Blood and Resolving Stasis on Atherosclerosis in Rats

YIN Xiao-jie, MAO Xiao-jing, WANG Lan, GONG Lei-lei, LI li, XIAO Yong-qing, LIANG Ri-xin^*

Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China

Received:2017-11-06 Revised:2017-11-06 Online:2017-09-20 Published:2017-11-06

摘要/Abstract

摘要： 目的观察三黄泻心汤“炮制配伍”活血化瘀优势方抗大鼠动脉粥样硬化（AS）作用。方法采用高脂饲料喂养联合维生素D₃注射及卵清蛋白诱发炎症的复合方法,复制大鼠动脉粥样硬化模型;实验分为正常对照组、模型组、模型组加阳性药（辛伐他汀,0.01g·kg^-1）及模型组加三黄泻心汤1.00 g·kg^-1、0.50 g·kg^-1、0.25 g·kg^-1 6组。造模8周后,开始给药,持续4周。于12周末,腹主动脉取血。测定如下指标：总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL）、低密度脂蛋白胆固醇（LDL）、超氧化物歧化酶（SOD）、丙二醛(MDA）、一氧化氮（NO）、超敏C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白介素1β（IL-1β）、白介素6（IL-6）、白介素8（IL-8）、白介素18（IL-18）、6-酮-前列腺素1α（6-keto-PGF_1α）、内皮素（ET）和血栓烷素B₂（TXB₂）。采血结束后,摘取主动脉,4%多聚甲醛固定,HE染色,显微镜下观察血管的病理变化情况。结果活血化瘀优势方能够降低TC、TG和LDL水平,升高HDL水平;提高SOD活性,降低MDA含量及CRP、TNF-α、IL-1β、IL-6、IL-8、IL-18等促炎因子的水平;使NO、6-keto-PGF_1α含量升高, ET和TXB₂含量降低;减少动脉壁脂质沉积及胆固醇结晶,改善钙化程度。结论活血化瘀优势方可能从调节血脂水平、抗氧化、抗炎性反应及改善内皮内皮细胞功能等方面对AS大鼠发挥保护作用。

关键词: 三黄泻心汤, 动脉粥样硬化, 炎性因子, 炮制配伍

Abstract: Objective To investigate effect of compound compatibility of processed Sanhuangxiexin decoction with activating blood and resolving stasis on atherosclerosis in rats. Methods The rat atherosclerosis model was established by a feeding of high-fat diet combined with injection of vitamin D₃ and ovalbumn. The rats were randomly divided into 6 groups, normal group, model group, model plus positive medicine group (simvastatin 0.01g·kg^-1 ) group, model plus compound compatibility groups at the dose of 1.00 g·kg^-1、0.50 g·kg^-1、0.25 g·kg^-1, respectively. After 8 weeks of modeling, the rats were administrated corresponding drugs for 4 weeks. At the end of 12 th week, blood was collected from the abdominal aorta to determine levels of following indicators: TC, TG, HDL, LDL, SOD, MDA, NO, CRP, TNF-α, IL-1, IL-6, IL-8, IL-18. RIA was used to determine content of 6-keto-PGF_1α, ET, and TXB₂. Then, the aorta was harvested and HE staining was used to observe pathological changes of blood vessels. Results The compound compatibility of processed Sanhuangxiexin decoction can reduce the content of TC, TG and LDL levels with increased HDL content. Meanwhile, SOD activity was increased, and MDA was reduced. The depressed contents of CRP, TNF-α, IL-1β, IL-6, IL-8, IL-18 were found. NO and 6-keto-PGF_1α contents were increased, and ET and TXB₂ were decreased. The pathological observation on the morphology and structure of vascular indicated that it could attenuate lipid deposition, cholesterol crystallization and calcification. Conclusion The compound compatibility of processed Sanhuangxiexin decoction may play an important role in the protection of AS rats, which may be related with regulating blood lipid levels, antioxidant and anti-inflammatory reaction, and improving endothelial functions.

Key words: Sanhuangxiexin decoction, atherosclerosis, inflammatory factors, compound compatibility

中图分类号:

R965

殷小杰, 马晓静, 王岚, 贡磊磊, 李丽, 肖永庆, 梁日欣. 三黄泻心汤“炮制配伍”活血化瘀优势方抗大鼠动脉粥样硬化作用的研究[J]. 中国药物警戒, 2017, 14(9): 518-522.

YIN Xiao-jie, MAO Xiao-jing, WANG Lan, GONG Lei-lei, LI li, XIAO Yong-qing, LIANG Ri-xin. Effect of Compound Compatibility of Processed Sanhuangxiexin Decoction with Activating Blood and Resolving Stasis on Atherosclerosis in Rats[J]. Chinese Journal of Pharmacovigilance, 2017, 14(9): 518-522.

参考文献

[1] Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature medicine, 2011,17(11): 1422-1422.
[2] 马晓静,王岚,殷小杰,等.三黄泻心汤“炮制配伍”解热优势方药效及其作用机制研究[J]. 中国药物警戒,2016,13(8)：449-463.
[3] 贡磊磊,殷小杰,王岚,等. “炮制配伍”三黄泻心汤9种组方的药效学比较研究[J]. 中国药物警戒,2015,12(1)：1-4.
[4] Cattellanos E, Sueishi K, Tanakak ,et al. Ultrastructural studies of rat atherosclerosis induced by stimulation of the immune system with ovalbumin[J]. Acta Pathol JPN, 1991,41(2):113-113.
[5] Michelsen K S, Doherty T M, Shah P K, et al. Role of Toll-like receptors in atherosclerosis[J]. Cir Res, 2012, 95(12): 96-96.
[6] Capron L. Pathogenesis of atherosclerosis: an update on the three main theories. Ann Cardiol Angeiol (Paris) 1989, 38:631-634.
[7] Cannon C P, Braunwald E, McCabe C H,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J]. N Engl J Med,2004,350(15):1495-1504.
[8] Ye N,Liu S,Lin Y, et al. Protective effects of intraperitoneal injectionof TAT-SOD against focal cerebral ischemia /reperfusion injuryin rats[J]. Life Sci,2011, 89( 23–24) : 868–874.
[9] 刘俊田. 动脉粥样硬化发病的炎症机制的研究进展[J]. 西安交通大学学报（医学版）,2015,36(2)：141-152.
[10] 于丽丽,赵捷,王慧媛,等. 白介素与动脉粥样硬化相关性研究进展[J].实用药物与临床,2014,17（9）：1182-1187.
[11] Ridker P M, Danielson E, Fonseca F A, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med, 2008,359(21): 2207-2207.
[12] Duewell P, Kono H, Rayner K J, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals[J]. Nature, 2010, 464(7293): 1361-1361.
[13] Mashudu M , Amanda G , Amanda L, et al. Endothelial dysfunction: the early predictor of atherosclerosis[J]. Cardiovascular Journal of Africa, 2012,123(4): 222-231.